Exercise of Options and Total Voting Rights

RNS Number : 5038I

Synairgen plc

12 August 2021

 

Press release 

Synairgen plc

('Synairgen' or the 'Company')

Exercise of Options

and Total Voting Rights

Southampton, UK - 12 August 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, announces today that it has allotted 1,427,423 new ordinary shares of 1 pence each in the capital of the company ("Ordinary Shares") following the exercise of share options ("Option Exercise") by certain directors of the Company as set out in the table below.

The options that have been exercised were due to expire in September 2021. Certain of the new ordinary shares have been sold, at a price of 140p, to meet the tax and subscription costs associated with the exercise, with the remaining shares being retained by the directors.  Following the exercise and subsequent sale, the holdings of the three directors are shown below:

Director	New Ordinary Shares Issued	New Ordinary Shares Sold	Resultant Options	Resultant Ordinary Shares	% of Total Voting Rights
Richard Marsden	538,063	296,959	2,279,513	995,771	0.49%
Dr Phillip Monk	400,212	220,878	1,646,323	423,934	0.21%
John Ward	489,148	269,963	1,772,958	734,092	0.36%

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around the 19th August 2021.

The new Ordinary Shares rank pari passu with the existing Ordinary Shares in the Company. Following the Option Exercise, the Company's issued share capital will consist of 201,341,825 Ordinary Shares. Accordingly, the figure of 201,341,825 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Jessica Hodgson, Carina Jurs

[e-mail]

Tel: [phone]

Notes for Editors

About Synairgen  

Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.

Synairgen is currently focused on developing its product candidate, SNG001 (inhaled interferon beta) for the treatment of COVID-19. SNG001 is potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. The Company is evaluating nebulised SNG001 in its Phase III clinical programme, which has been deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). SNG001 has also been granted Fast Track status from the US Food and Drug Administration (FDA). In a Phase II trial, COVID-19 patients with marked/severe breathlessness demonstrated a threefold greater chance of recovery when treated with SNG001 versus placebo.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Richard Marsden
2.	Reason for notification
a)	Position / status	Chief Executive Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Exercise of options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Exercise of options
c)	Price(s) and volume(s)	Price(s) Volume(s) 1p 538,063
d)	Aggregated information Aggregated volume Price	As above
e)	Date of the transaction	12 August 2021
f)	Place of the transaction	London AIM

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Richard Marsden
2.	Reason for notification
a)	Position / status	Chief Executive Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Sale of ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 140p 296,959
d)	Aggregated information Aggregated volume Price	As above
e)	Date of the transaction	12 August 2021
f)	Place of the transaction	London AIM

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Dr Phillip Monk
2.	Reason for notification
a)	Position / status	Chief Scientific Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Exercise of options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Exercise of options
c)	Price(s) and volume(s)	Price(s) Volume(s) 1p 400,212
d)	Aggregated information Aggregated volume Price	As above
e)	Date of the transaction	12 August 2021
f)	Place of the transaction	London AIM

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Dr Phillip Monk
2.	Reason for notification
a)	Position / status	Chief Scientific Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Sale of ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 140p 220,878
d)	Aggregated information Aggregated volume Price	As above
e)	Date of the transaction	12 August 2021
f)	Place of the transaction	London AIM

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	John Ward
2.	Reason for notification
a)	Position / status	Chief Financial Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Exercise of options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Exercise of options
c)	Price(s) and volume(s)	Price(s) Volume(s) 1p 489,148
d)	Aggregated information Aggregated volume Price	As above
e)	Date of the transaction	12 August 2021
f)	Place of the transaction	London AIM

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	John Ward
2.	Reason for notification
a)	Position / status	Chief Financial Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Sale of ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 140p 269,963
d)	Aggregated information Aggregated volume Price	As above
e)	Date of the transaction	12 August 2021
f)	Place of the transaction	London AIM

 

END

 

 

DSHMZGMRKZMGMZM